- Home
- AAUC vs ADPT Comparison
AAUC vs ADPT Comparison
Compare AAUC & ADPT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- AAUC
- ADPT
- Stock Information
- Founded
- AAUC N/A
- ADPT 2009
- Country
- AAUC Canada
- ADPT United States
- Employees
- AAUC N/A
- ADPT N/A
- Industry
- AAUC
- ADPT Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- AAUC
- ADPT Health Care
- Exchange
- AAUC Nasdaq
- ADPT Nasdaq
- Market Cap
- AAUC 1.5B
- ADPT 1.8B
- IPO Year
- AAUC N/A
- ADPT 2019
- Fundamental
- Price
- AAUC $13.50
- ADPT $13.00
- Analyst Decision
- AAUC
- ADPT Strong Buy
- Analyst Count
- AAUC 0
- ADPT 8
- Target Price
- AAUC N/A
- ADPT $12.38
- AVG Volume (30 Days)
- AAUC 159.2K
- ADPT 2.2M
- Earning Date
- AAUC 08-08-2025
- ADPT 08-05-2025
- Dividend Yield
- AAUC N/A
- ADPT N/A
- EPS Growth
- AAUC N/A
- ADPT N/A
- EPS
- AAUC N/A
- ADPT N/A
- Revenue
- AAUC $958,087,000.00
- ADPT $205,216,000.00
- Revenue This Year
- AAUC $68.13
- ADPT $32.76
- Revenue Next Year
- AAUC $32.41
- ADPT $15.81
- P/E Ratio
- AAUC N/A
- ADPT N/A
- Revenue Growth
- AAUC 31.78
- ADPT 21.60
- 52 Week Low
- AAUC $11.40
- ADPT $3.98
- 52 Week High
- AAUC $15.79
- ADPT $13.40
- Technical
- Relative Strength Index (RSI)
- AAUC 56.61
- ADPT 64.48
- Support Level
- AAUC $11.90
- ADPT $12.10
- Resistance Level
- AAUC $13.74
- ADPT $13.37
- Average True Range (ATR)
- AAUC 0.59
- ADPT 0.87
- MACD
- AAUC 0.15
- ADPT 0.06
- Stochastic Oscillator
- AAUC 89.36
- ADPT 85.74
About AAUC Allied Gold Corporation Common Shares
Allied Gold Corp is a company focused on gold mining activities in Africa. Allied has three mines and several development and exploration projects in Africa where it has operating experience. Operations are located in Cote d'Ivoire, Mali, and Ethiopia. The company expands and optimizes initiatives at existing operating mines, the development of new mines, the advancement of its exploration properties, and, targeting other consolidation opportunities with a focus on Africa.
About ADPT Adaptive Biotechnologies Corporation
Adaptive Biotechnologies Corp is a company advancing the field of immune-driven medicine by harnessing the inherent biology of the adaptive immune system to transform the diagnosis and treatment of disease. Its clinical diagnostic product, clonoSEQ, is test authorized by the FDA for the detection and monitoring of minimal residual disease (MRD) in patients with multiple myeloma (MM), B cell acute lymphoblastic leukemia (ALL) and chronic lymphocytic leukemia (CLL) and is also available as a CLIA-validated laboratory developed test (LDT) for patients with other lymphoid cancers, including diffuse large B-cell lymphoma (DLBCL).